Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Negocios · 8/6/20221 min de lectura
Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary- Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2024, expiration date.
Idioma original de la fuente: Federal Register — Food and Drug AdministrationAbrir el comunicado original →